Aileron Therapeutics Inc expected to post a loss of 7 cents a share - Earnings Preview

Rein Therapeutics

09/11/2021 03:07

* Aileron Therapeutics Inc  ALRN.OQ   ALRN.O  is expected
to show no change in quarterly revenue when it reports 
results on November 10 (estimated). 
​* Refinitiv's mean analyst estimate for Aileron Therapeutics
Inc is for a loss of 7 cents per share. For the same quarter
last year, the company reported a loss of 13 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Aileron
Therapeutics Inc is $3.5​, about 74.5% above​ its last closing
price of $0.89. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Jun. 30 2021  -0.07       -0.07      -0.06     Beat    18.2
 Mar. 31 2021  -0.05       -0.05      -0.08     Missed  -50
 Dec. 31 2020  -0.12       -0.13      -0.12     Beat    5.9​
 Sep. 30 2020  -0.13       -0.15      -0.13     Beat    12.2
 ​​Jun.        -0.16       -0.19      -0.14     Beat    25.3
 30 2020                                                
 Mar. 31 2020  -0.20       -0.20      -0.24     Missed  -18.5​
 Dec. 31 2019              -0.27      -0.26     Beat    4.6
 Sep. 30 2019  -0.25       -0.24      -0.28     Missed  -17.9
 This summary was machine generated November 9 at 03:07 GMT.  All
figures in US dollars unless otherwise stated